In This Article:
As U.S. markets show resilience with rising stocks and dipping yields, investors are increasingly exploring diverse opportunities to capitalize on potential growth. Penny stocks, a term that might seem outdated, continue to offer intriguing possibilities for those willing to look beyond the big names. These often smaller or newer companies can present a compelling mix of affordability and growth potential when backed by strong financials, making them an attractive option for discerning investors.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Financial Health Rating |
| BAB (OTCPK:BABB) | $0.88875 | $6.46M | ★★★★★★ |
| QuantaSing Group (NasdaqGM:QSG) | $3.08 | $125.23M | ★★★★★★ |
| Golden Growers Cooperative (OTCPK:GGRO.U) | $4.50 | $67.38M | ★★★★★★ |
| Imperial Petroleum (NasdaqCM:IMPP) | $2.94 | $89.18M | ★★★★★★ |
| North European Oil Royalty Trust (NYSE:NRT) | $4.71 | $43.29M | ★★★★★★ |
| Permianville Royalty Trust (NYSE:PVL) | $1.42 | $46.86M | ★★★★★★ |
| BTCS (NasdaqCM:BTCS) | $2.69 | $46.67M | ★★★★★★ |
| Smith Micro Software (NasdaqCM:SMSI) | $1.41 | $25.01M | ★★★★★☆ |
| CBAK Energy Technology (NasdaqCM:CBAT) | $0.8834 | $79.45M | ★★★★★☆ |
| Safe Bulkers (NYSE:SB) | $3.60 | $384.4M | ★★★★☆☆ |
Click here to see the full list of 709 stocks from our US Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Giftify
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Giftify, Inc. owns and operates a restaurant deal space in the United States with a market cap of $29.57 million.
Operations: The company generates revenue of $86.44 million from its direct marketing segment.
Market Cap: $29.57M
Giftify, Inc., with a market cap of US$29.57 million, operates in the restaurant deal space and is currently unprofitable. Despite generating US$86.44 million in revenue from its direct marketing segment, losses have increased over the past five years by 27.1% annually. The company's short-term assets do not cover its liabilities, but long-term liabilities are adequately managed with short-term assets exceeding them by US$4.4 million. Recent financial activities include a private placement raising US$2 million and a follow-on equity offering of US$0.6 million to bolster cash reserves amidst volatile share prices and ongoing strategic acquisition pursuits following its Nasdaq uplisting.
-
Dive into the specifics of Giftify here with our thorough balance sheet health report.
-
Examine Giftify's earnings growth report to understand how analysts expect it to perform.
CureVac
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: CureVac N.V. is a biopharmaceutical company that develops transformative medicines using messenger ribonucleic acid (mRNA) technology, with a market cap of $803.04 million.